823-58-5

Basic information

• Product Name: 3,6-dichloropyridazin-4-amine
• Synonyms: 3,6-dichloropyridazin-4-amine;4-Amino-3,6-dihydropyridazine;3,6-Dichloro-4-Pyridazinamine;3,6-Dichloro-4-aMinopyridazine;4-AMino-3,6-dichloropyridazine;4-AMino-3,6-dicholropyridazine;4-PyridazinaMine, 3,6-dichloro-;NSC 170664
• CAS NO: 823-58-5
• Molecular Formula: C₄H₃Cl₂N₃
• Molecular Weight: 163.99
• Mol File: 823-58-5.mol
• Article Data: 14

Chemical Properties

• Melting Point: 203 °C
• Boiling Point: 363 °C at 760 mmHg
• Flash Point: 173.3 °C
• Appearance: /
• Density: 1.606 g/cm³
• Vapor Pressure: 1.86E-05mmHg at 25°C
• Refractive Index: 1.633
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 2.08±0.10(Predicted)
• CAS DataBase Reference: 3,6-dichloropyridazin-4-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 3,6-dichloropyridazin-4-amine(823-58-5)
• EPA Substance Registry System: 3,6-dichloropyridazin-4-amine(823-58-5)

Safety Data

• Hazardous Substances Data: 823-58-5(Hazardous Substances Data)

Usage

General Description

3,6-dichloropyridazin-4-amine is a chemical compound with the molecular formula C4H3Cl2N3. It is a derivative of pyridazine, a six-membered ring containing two adjacent nitrogen atoms and four carbon atoms. 3,6-dichloropyridazin-4-amine is primarily used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. It is also used in the development of various nitrogen-containing heterocycles. Due to its potential reactivity and toxicity, appropriate safety measures should be observed when handling and working with 3,6-dichloropyridazin-4-amine.

InChI:InChI=1/C4H3Cl2N3/c5-3-1-2(7)4(6)9-8-3/h1H,(H2,7,8)

Upstream product

• 6082-66-2 3,4,6-trichloropyridazine 
• 17285-22-2 5-amino-6-chloro-3(2H)-pyridazinone 
• 887310-61-4 (3,6-dichloro-pyridazin-4-yl)-carbamic acid tert-butyl ester 
• 1104202-03-0 C₈H₂Cl₄N₄Zn 
• 10344-42-0 4-bromo-3,6-dichloro-pyridazine 
• 7664-41-7 ammonia 

Downstream Products

• 111163-93-0 6-chloro-2-phenyl-oxazolo[5,4-c]pyridazine 
• 20744-39-2 4-aminopyridazine 
• 887310-62-5 3,6-dichloro-N-tritylpyridazin-4-amine 
• 934-26-9 4-amino-6-chloro-3-hydrazinopyridazine 
• 14369-14-3 4-amino-6-chloro-3-methoxypyridazine 
• 79852-16-7 5-Amino-3-chloro-6-phenylpyridazine 
• 28682-68-0 4-amino-3,6-dichloro-5-nitropyridazine 

Relevant articles and documents

Chemical Proteomic Profiling of Bromodomains Enables the Wide-Spectrum Evaluation of Bromodomain Inhibitors in Living Cells

Bromodomains, epigenetic "readers" of lysine acetylation marks, exist in different nuclear proteins with diverse biological functions in chromatin biology. Malfunctions of bromodomains are associated with the pathogenesis of human diseases, such as cancer. Bromodomains have therefore emerged as therapeutic targets for drug discovery. Given the high structural similarity of bromodomains, a critical step in the development of bromodomain inhibitors is the evaluation of their selectivity to avoid off-target effects. While numerous bromodomain inhibitors have been identified, new methods to evaluate the inhibitor selectivity toward endogenous bromodomains in living cells remain needed. Here we report the development of a photoaffinity probe, photo-bromosporine (photo-BS), that enables the wide-spectrum profiling of bromodomain inhibitors in living cells. Photo-BS allowed light-induced cross-linking of recombinant bromodomains and endogenous bromodomain-containing proteins (BCPs) both in vitro and in living cells. The photo-BS-induced labeling of the bromodomains was selectively competed by the corresponding bromodomain inhibitors. Proteomics analysis revealed that photo-BS captured 28 out of the 42 known BCPs from the living cells. Assessment of the two bromodomain inhibitors, bromosporine and GSK6853, resulted in the identification of known as well as previously uncharacterized bromodomain targets. Collectively, we established a chemical proteomics platform to comprehensively evaluate bromodomain inhibitors in terms of their selectivity against endogenous BCPs in living cells.

Site-Selective Copper-Catalyzed Amination and Azidation of Arenes and Heteroarenes via Deprotonative Zincation

Arene amination is achieved by site-selective C-H zincation followed by copper-catalyzed coupling with O-benzoylhydroxylamines under mild conditions. Key to this success is ortho-zincation mediated by lithium amidodiethylzincate base that is effective for a wide range of arenes, including nonactivated arenes bearing simple functionalities such as fluoride, chloride, ester, amide, ether, nitrile, and trifluoromethyl groups as well as heteroarenes including indole, thiophene, pyridine, and isoquinoline. An analogous C-H azidation is also accomplished using azidoiodinane for direct introduction of a useful azide group onto a broad scope of arenes and heteroarenes. These new transformations offer rapid access to valuable and diverse chemical space of aminoarenes. Their broad applications in organic synthesis and drug discovery are demonstrated in the synthesis of novel analogues of natural product (-)-nicotine and antidepressant sertraline by late-stage amination and azidation reactions.

SUBSTITUTED TRICYCLICS AND METHOD OF USE

The present invention provides for compounds of formula (I) wherein X, Y, and R1 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sj?gren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).